Cost-effectiveness analysis of larotrectinib vs standard of care for treatment of metastatic NTRK fusion colorectal cancer
From the perspective of healthcare payers in China, larotrectinib was cost-effective compared to standard of care as a second-line treatment or subsequent treatment for advanced or metastatic CRC patients with NTRK gene fusion-positive.
Authors
- Lu Zhong (ORCID: https://orcid.org/0009-0004-0910-0515)
- Tong Liu (ORCID: https://orcid.org/0000-0002-1389-7051)
- Mei Dong (ORCID: https://orcid.org/0000-0002-2944-6853)
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1080/14737167.2025.2603943
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00